Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors

A compound of Formula (I):

• wherein:
• R1 is hydrogen or halo;
• ring RA is a ring of formula (i), (ii), (iii), or (iv):
• where alk is alkyl and each ring of RA is substituted with R4 and R5 independently selected from hydrogen, alkyl, and halo;
• R2 and R3 are independently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
• ring RB is cycloalkyl, bridged cycloalkyl, heterocyclyl, or bridged heterocyclyl,
• wherein:
• (A) cycloalkyl and bridged cycloalkyl of ring RB are substituted with Ra selected from hydrogen, halo, haloalkyl, and hydroxalkyl;
• (B) heterocyclyl of ring RB is substituted with Rb, Rc, and Rd where Rb and Rc are independently selected from hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy and Rd is hydrogen, alkyl, deuteroalkyl, cycloalkyl (optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, and cyano), alkoxy, halo, haloalkyl, haloalkoxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, aryl, aralkyl, heterocyclyl, or heteroaryl;
• and
• (C) bridged heterocyclyl of ring RB is substituted with Re, Rf, and Rg where Re and Rf are independently selected from hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkyl, and haloalkoxy and Rg is hydrogen, alkyl, deuteroalkyl, cycloalkyl (optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxy, or cyano), alkoxy, halo, haloalkyl, haloalkoxy, alkoxycarbonyl, oxo, amino, alkylamino, dialkylamino, aryl, aralkyl, heterocyclyl, or heteroaryl;
• or
• a pharmaceutically acceptable salt thereof.